文献速递心境障碍儿童青少年精神精神分裂症与精神病性障碍

氟伏沙明治疗COVID-19的作用机制:历史性综述

Mechanisms of action of fluvoxamine for COVID-19: a historical review.
PubMed 文献 · Mol Psychiatry · 2022-01-07

本综述回顾氟伏沙明对COVID-19的作用机制,涉及5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。文章还讨论母亲COVID-19感染与子代神经精神障碍(如孤独症谱系障碍和精神分裂症)风险的可能联系。

要点

  • 氟伏沙明对COVID-19的作用机制涉及5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。
  • 抗抑郁药用于早期COVID-19可能减少插管或死亡风险。
  • 氟伏沙明被认为是轻中度COVID-19患者最具吸引力的抗抑郁药。

核心结论

  • 抗抑郁药用于早期COVID-19受试者可能降低插管或死亡风险,氟伏沙明是其中最具吸引力的药物。

研究设计与样本

  • 历史性综述,回顾氟伏沙明对COVID-19的作用机制。

主要发现

  • 氟伏沙明的作用机制包括5-羟色胺转运体、sigma-1受体和酸性鞘磷脂酶。
  • 越来越多的临床数据显示抗抑郁药用于早期COVID-19受试者可能与降低插管或死亡风险相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hashimoto Y, Suzuki T, Hashimoto K, et al. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022. PMID: 34997196. doi:10.1038/s41380-021-01432-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。